Fruzaqla was licensed by Takeda from China's Hutchmed for $400 million upfront in 2023 and has also been approved in the US ...

A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to big pharma, too, in terms of restructuring and refocusing – even in terms of ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

UK Prime Minister Sir Keir Starmer is due to reveal the long-awaited 10 Year Plan for the NHS later today, but revealed some ...

Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced ...

The UK’s regulator, the MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence ...

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in ...